We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives. Within an assigned portfolio of products, platforms, assets or sites, the role translates portfolio growth, demand, lifecycle and business requirements into integrated capacity, footprint, sourcing, asset and site strategies that enable supply continuity, operational performance and future growth.